Competition and price among brand-name drugs in the same class: A systematic review of the evidence

PLoS Medicine
Ameet SarpatwariAaron S Kesselheim

Abstract

Some experts have proposed combating rising drug prices by promoting brand-brand competition, a situation that is supposed to arise when multiple US Food and Drug Administration (FDA)-approved brand-name products in the same class are indicated for the same condition. However, numerous reports exist of price increases following the introduction of brand-name competition, suggesting that it may not be effective. We performed a systematic literature review of the peer-reviewed health policy and economics literature to better understand the interplay between new drug entry and intraclass drug prices. We searched PubMed and EconLit for original studies on brand-brand competition in the US market published in English between January 1990 and April 2019. We performed a qualitative synthesis of each study's data, recording its primary objective, methodology, and results. We found 10 empirical investigations, with 1 study each on antihypertensives, anti-infectives, central nervous system stimulants for attention deficit/hyperactivity disorder, disease-modifying therapies for multiple sclerosis, histamine-2 (H2) blockers, and tumor necrosis factor (TNF) inhibitors; 2 studies on cancer medications; and 2 studies on all marketed or new dr...Continue Reading

References

Apr 12, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Joel Lexchin
Sep 28, 2007·PLoS Medicine·G Michael AllanNatasha Wiebe
Mar 6, 2008·JAMA : the Journal of the American Medical Association·Rebecca L WaberDan Ariely
Feb 18, 2011·JAMA : the Journal of the American Medical Association·Joshua J Gagne, Niteesh K Choudhry
Dec 15, 2012·Journal of Health Economics·Maria-Angeles de FrutosGeorges Siotis
Jan 30, 2015·Neurology·Alberto J EspayJerzy P Szaflarski
Jun 1, 2013·The Journal of Industrial Economics·Farasat A S Bokhari, Gary M Fournier
May 7, 2015·The New England Journal of Medicine·Ameet SarpatwariAaron S Kesselheim
Aug 24, 2016·JAMA : the Journal of the American Medical Association·Aaron S KesselheimAmeet Sarpatwari
Jan 25, 2017·JAMA : the Journal of the American Medical Association·Jerry Avorn
Jan 1, 2015·The Journal of Economic Perspectives : a Journal of the American Economic Association·David H HowardRena M Conti
Oct 11, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Noa GordonDaniel A Goldstein
Dec 28, 2017·The New England Journal of Medicine·Chintan V DaveAaron S Kesselheim
May 26, 2018·JAMA : the Journal of the American Medical Association·Ameet SarpatwariAaron S Kesselheim
Nov 12, 2018·Clinical Pharmacology and Therapeutics·Ameet SarpatwariAaron S Kesselheim
Jan 9, 2019·JAMA : the Journal of the American Medical Association·Lisa M Schwartz, Steven Woloshin
Feb 19, 2019·JAMA Internal Medicine·Alvaro San-Juan-RodriguezInmaculada Hernandez
Jul 2, 2019·Health Affairs·Ariel D SternAmeet Sarpatwari

❮ Previous
Next ❯

Software Mentioned

EconLit

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

PharmacoEconomics
N Bosanquet, J Zammit-Lucia
Hospital Material[dollar Sign] Management
T C Brightbill
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne
Joel Lexchin
© 2021 Meta ULC. All rights reserved